Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday.

Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion.

Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion.

Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

A doctor examining a patient’s samples in a modern hospital setting.

In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.

The upfront offer price represents a 27-percent premium over Blueprint’s closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025.

The purchase will also include the latter’s rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM).

Overall, BPMC ranks 4th on our list of top-performing stocks on Monday. While we acknowledge the potential of BPMC, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BPMC and that has 10,000x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.